145 related articles for article (PubMed ID: 37902443)
1. Healthcare resource utilization and costs among patients with post-stroke spasticity before and after spasticity management including onabotulinumtoxina.
Esquenazi A; Bloudek L; Migliaccio-Walle K; Oliveri D; Tung A; Gillard P; Verduzco-Gutierrez M
J Rehabil Med; 2023 Oct; 55():jrm11626. PubMed ID: 37902443
[TBL] [Abstract][Full Text] [Related]
2. Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
Hull M; Anupindi VR; DeKoven M; He J; Bouchard J
Adv Ther; 2023 Sep; 40(9):3986-4003. PubMed ID: 37414904
[TBL] [Abstract][Full Text] [Related]
3. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
5. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Kazerooni R; Watanabe JH
J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
[No Abstract] [Full Text] [Related]
6. OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial.
Wissel J; Ganapathy V; Ward AB; Borg J; Ertzgaard P; Herrmann C; Haggstrom A; Sakel M; Ma J; Dimitrova R; Fulford-Smith A; Gillard P
J Pain Symptom Manage; 2016 Jul; 52(1):17-26. PubMed ID: 27037050
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
8. Real-world differences in dosing and clinical utilization of OnabotulinumtoxinA and AbobotulinumtoxinA in the treatment of upper limb spasticity.
Bohart Z; Dashtipour K; Kim H; Schwartz M; Zuzek A; Singh R; Nelson M
Toxicon; 2024 Apr; 241():107678. PubMed ID: 38447766
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
Danchenko N; Johnston KM; Whalen J
J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
Esquenazi A; Bavikatte G; Bandari DS; Jost WH; Munin MC; Tang SFT; Largent J; Adams AM; Zuzek A; Francisco GE
PM R; 2021 Oct; 13(10):1079-1093. PubMed ID: 33151636
[TBL] [Abstract][Full Text] [Related]
11. Safety of OnabotulinumtoxinA with Concomitant Antithrombotic Therapy in Patients with Muscle Spasticity: A Retrospective Pooled Analysis of Randomized Double-Blind Studies.
Dimitrova R; James L; Liu C; Orejudos A; Yushmanova I; Brin MF
CNS Drugs; 2020 Apr; 34(4):433-445. PubMed ID: 32170665
[TBL] [Abstract][Full Text] [Related]
12. Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
Kazerooni R; Howard I; Li X; Verduzco-Gutierrez M
Arch Phys Med Rehabil; 2022 Jun; 103(6):1205-1209. PubMed ID: 34852255
[TBL] [Abstract][Full Text] [Related]
13. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland.
Doan QV; Gillard P; Brashear A; Halperin M; Hayward E; Varon S; Lu ZJ
Eur J Neurol; 2013 May; 20(5):773-80. PubMed ID: 23278954
[TBL] [Abstract][Full Text] [Related]
15. Direct health care costs associated with COVID-19 in the United States.
DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
[No Abstract] [Full Text] [Related]
16. Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study.
Francisco GE; Jost WH; Bavikatte G; Bandari DS; Tang SFT; Munin MC; Largent J; Adams AM; Zuzek A; Esquenazi A
PM R; 2020 Nov; 12(11):1120-1133. PubMed ID: 31953896
[TBL] [Abstract][Full Text] [Related]
17. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
Bensmail D; Hanschmann A; Wissel J
J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
[TBL] [Abstract][Full Text] [Related]
18. Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity: A Randomized Trial.
Esquenazi A; Wein TH; Ward AB; Geis C; Liu C; Dimitrova R
Am J Phys Med Rehabil; 2019 May; 98(5):360-368. PubMed ID: 31003229
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
[TBL] [Abstract][Full Text] [Related]
20. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
